Show simple item record

dc.contributor.authorCompston, Julieten
dc.contributor.authorCooper, Aen
dc.contributor.authorCooper, Cen
dc.contributor.authorGittoes, Nen
dc.contributor.authorGregson, Cen
dc.contributor.authorHarvey, Nen
dc.contributor.authorHope, Sen
dc.contributor.authorKanis, JAen
dc.contributor.authorMcCloskey, EVen
dc.contributor.authorPoole, Kennethen
dc.contributor.authorReid, DMen
dc.contributor.authorSelby, Pen
dc.contributor.authorThompson, Fen
dc.contributor.authorThurston, Aen
dc.contributor.authorVine, Nen
dc.contributor.authorNational Osteoporosis Guideline Group (NOGG),en
dc.date.accessioned2017-09-11T14:11:20Z
dc.date.available2017-09-11T14:11:20Z
dc.date.issued2017-12en
dc.identifier.issn1862-3522
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/267137
dc.description.abstractINTRODUCTION: In 2008, the UK National Osteoporosis Guideline Group (NOGG) produced a guideline on the prevention and treatment of osteoporosis, with an update in 2013. This paper presents a major update of the guideline, the scope of which is to review the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women and men age 50 years or over. METHODS: Where available, systematic reviews, meta-analyses and randomised controlled trials were used to provide the evidence base. Conclusions and recommendations were systematically graded according to the strength of the available evidence. RESULTS: Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment, lifestyle measures and pharmacological interventions, duration and monitoring of bisphosphonate therapy, glucocorticoid-induced osteoporosis, osteoporosis in men, postfracture care and intervention thresholds. CONCLUSION: The guideline, which has received accreditation from the National Institute of Health and Care Excellence (NICE), provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals who are involved in its management.
dc.languageengen
dc.language.isoenen
dc.publisherSpringer Nature
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectFractureen
dc.subjectGuidelineen
dc.subjectNOGGen
dc.subjectOsteoporosisen
dc.subjectAgeden
dc.subjectBone Density Conservation Agentsen
dc.subjectDiphosphonatesen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLife Styleen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectOsteoporosisen
dc.subjectOsteoporotic Fracturesen
dc.subjectPractice Guidelines as Topicen
dc.subjectRisk Assessmenten
dc.subjectUnited Kingdomen
dc.titleUK clinical guideline for the prevention and treatment of osteoporosisen
dc.typeArticle
prism.endingPage43
prism.issueIdentifier1en
prism.publicationDate2017en
prism.publicationNameArchives of Osteoporosisen
prism.startingPage43
prism.volume12en
dc.identifier.doi10.17863/CAM.13153
dcterms.dateAccepted2017-03-07en
rioxxterms.versionofrecord10.1007/s11657-017-0324-5en
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2017-12en
dc.contributor.orcidCompston, Juliet [0000-0001-5660-4151]
dc.contributor.orcidPoole, Kenneth [0000-0003-4546-7352]
dc.identifier.eissn1862-3514
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idNational Institute for Health Research ()
pubs.funder-project-idCambridge University Hospitals NHS Foundation Trust (CUH) (146281)
cam.issuedOnline2017-04-19en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International